14-CpG-Based Signature Improves the Prognosis Prediction of Hepatocellular Carcinoma Patients

Figure 5

Stratified survival analysis based on major clinicopathological factors. The 14-CpG-based signature exhibited good prognostic value in different subgroups classified by AFP (a-b), cirrhosis (c-d), Child-Pugh A (e), tumor histologic grade (f-g), and AJCC stage (h-i). (a) Patients with AFP (<25) (N = 166). (b) Patients with AFP (>25) (N = 116). (c) Patients without cirrhosis (N = 136). (d) Patients with cirrhosis (N = 79). (e) Patients with Child-Pugh A (N = 222). (f) Patients with histologic grade G1/G2 (N = 233). (g) Patients with histologic grade G3/G4 (N = 132). (h) Patients with AJCC stage I/II (N = 259). (i) Patients with AJCC stage I/II (N = 88).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)